DataMeds AI, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $MEDS in the last 7 days.
No SEC Form 4 filings for $MEDS in the last 30 days.
See all $MEDS insider activity →DataMeds AI reported Corexa Pharmacy's September revenue exceeded $1M, a 66% increase from July 2026, driven by retail growth and new product launches. The company attributes this to recent rebranding and new offerings.
DataMeds AI (NASDAQ:MEDS) shares rose 31.83% to $4.10 Monday after launching its 'Health Lives Here' app with Tollo Health and NFL Alumni Association. The app offers telemedicine, pharmacy services, and AI health coaching, with plans to expand to Long COVID and oncology patients by 2026. The company aims to add digital twin and blockchain features by 2027.
DataMeds AI stock rose 25% after launching the Health Lives Here app, targeting GLP-1 medication users. The app integrates telemedicine, prescriptions, and health tracking. The company plans to expand to Long COVID and cancer patients, and is building a national pharmacy network. DataMeds AI aims to create a comprehensive healthcare platform.
Recent MEDS coverage spans market movers, mergers & acquisitions and corporate actions.
Modest positive pressure as the revenue milestone suggests early traction.
The app launch provides a new growth avenue and partnership with NFL Alumni, likely driving further buying interest.
DataMeds AI stock rose 25% after launching the Health Lives Here app, targeting GLP-1 medication users. The app integrates telemedicine, prescriptions, and health tracking. The company plans to expand to Long COVID and cancer patients, and is building a national pharmacy network. DataMeds AI aims to create a comprehensive healthcare platform.
The website launch signals integration of the newly acquired AI diagnostics assets and removal of debt, likely supporting short‑term upside.
The deal adds oncology data assets to MEDS, potentially expanding its market and justifying the sharp price jump.
AlphAI scores every news story that mentions MEDS with an AI model for sentiment and relevance, and aggregates insider trades from DataMeds AI, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
DataMeds AI reported Corexa Pharmacy's September revenue exceeded $1M, a 66% increase from July 2026, driven by retail growth and new product launches. The company attributes this to recent rebranding and new offerings.
1 min readDataMeds AI (NASDAQ:MEDS) shares rose 31.83% to $4.10 Monday after launching its 'Health Lives Here' app with Tollo Health and NFL Alumni Association. The app offers telemedicine, pharmacy services, and AI health coaching, with plans to expand to Long COVID and oncology patients by 2026. The company aims to add digital twin and blockchain features by 2027.
2 min readDataMeds AI stock rose 25% after launching the Health Lives Here app, targeting GLP-1 medication users. The app integrates telemedicine, prescriptions, and health tracking. The company plans to expand to Long COVID and cancer patients, and is building a national pharmacy network. DataMeds AI aims to create a comprehensive healthcare platform.
2 min readDataMeds AI Inc (NASDAQ:MEDS) shares rose 7.5% premarket after launching a new website post-acquisition. The company acquired Helomics' AI Cancer Diagnostics Lab, settled litigation, and plans to launch the Health Lives Here app. The website reflects AI-focused marketing efforts, according to the company.
1 min readDataMeds AI (MEDS) stock surged 198.16% after acquiring Helomics, a cancer diagnostics business, from Axe Compute (AGPU) in exchange for shares. Helomics focuses on AI-driven cancer care and drug discovery. DataMeds AI plans to integrate Helomics' data and tools into its platform. MEDS stock is down 87.98% year-to-date and 98.74% over the past year, with heavy trading volume on the news.
2 min readDataMEDS (MEDS) is being acquired by Axe, potentially yielding $7.5M pre-tax. MEDS stock has declined since a Sept. 16 surge. Q2 2026 revenue was $1.78M, down 77% YoY, with Q1 2026 revenue down 86% YoY. The low valuation and falling sales make MEDS stock unattractive, according to the analysis.
2 min readDataMeds AI (NASDAQ:MEDS) settled litigation, extinguishing ~$19M in liabilities and retiring 364,099 common shares. The company paid $450,000 in cash. This resolves debt and receivables from a 2023 agreement, allowing the company to focus on healthcare solutions.
2 min readDataMeds AI, Inc. (MEDS) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 11, 2026, DataMEDS AI, Inc. (the “Company”) entered into a settlement agreement and release (the “Agreement”) with Brian Norton, individually and as Seller Representative (“Norton”), Tony Madsen, Mark DiSiena, T. Scott Madsen, Stephen J. Madse
2 min readAxe Compute Inc. (AGPU) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Axe Compute Sells Helomics AI Cancer Diagnostics Lab Business to DataMEDS AI, Completing Transition to Neocloud GPU-as-a-Service platform September 15, 2026 All-stock sale gives Axe Compute equity stake in DataMEDS AI; aligns APU’s operating structure with its scalin
2 min readDataMEDS AI (MEDS) rose 295.53% after acquiring Helomics for $1.5M, expanding into precision oncology. Tempest Therapeutics (TPST) gained 58.86% with a CAR-T licensing deal. NeurAxis (NRXS) increased 22.63% on expanded insurance coverage for its PENFS therapy. MAIA Biotechnology (MAIA) rose 5.22% after dosing the first U.S. patient in its THIO-101 trial.
3 min read
